Physician profile
David Leeman
NPI 1215925045
$1,010.14
in general payments reported to CMS, 2019-2025
12 companies · $44.18 in 2025
The $44.18 reported for 2025 was less than what a typical Emergency Medical Services provider received nationally (typical 2025 total: $70.35).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.09 · 2020: $57.63 · 2021: $116 · 2022: $299 · 2023: $283 · 2024: $179 · 2025: $44.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $506.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $413.51 | 2020-2024 | Brilinta, Andexxa |
| Pfizer INC. | $184.11 | 2019-2025 | |
| Csl Behring | $75.81 | 2022-2024 | Kcentra |
| Alexion Pharmaceuticals, INC. | $71.93 | 2021-2022 | |
| Chiesi USA, INC. | $56.74 | 2021-2022 | |
| Octapharma USA, INC. | $45.77 | 2024 | Balfaxar |
| Ucb, INC. | $45.50 | 2023 | Nayzilam |
| E.R. Squibb & Sons, L.L.C. | $44.28 | 2019-2021 | |
| Kedrion Biopharma, INC. | $24.96 | 2025 | Gammaked, Rhogam Ultra-Filtered Plus, Albuked |
| Ambu INC. | $21.05 | 2022 | |
| Lundbeck LLC | $14.06 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Leeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.